Table 1 Timeline of patient biochemical characteristics
From: Case report: coexistence of primary hyperparathyroidism with giant toxic nodular goiter
Subject | FT3 (2.76-6.3pmol/L) | FT4 (10.42–24.32 pmol/L) | TSH (0.35-5.5mU/L) | CA (2.09-2.54mmol/L) | P (0.89-1.6mmol/L) | PTH (15-65pg/mL) | 25-(OH) D3 (20–32 ng/mL) | |
|---|---|---|---|---|---|---|---|---|
2010 | Elevated thyroid hormone and decreased TSH level | NA | ||||||
2013 | NA | NA | ||||||
2019 | 7.82 | 49.79 | 0.01 | 3.24 | 0.62 | 90.78 | NA | |
2021.06 (Pre-operation) | 5.04 | 13.05 | 1.63 | 2.75 | 0.76 | 140.60 | 16.90 | |
2021.07 (Post-operation) | 3.80 | 13.26 | 3.22 | 2.83 | 0.66 | 125.00 | 14.70 | |
2021.10 | 5.58 | 21.52 | 0.49 | 2.76 | 0.70 | 134.60 | 15.20 | |
2021.11. (Pre- MWA) | NA | 2.77 | 0.77 | 106 | 15.7 | |||
2021.11 (2 h Post-MWA) | NA | 2.98 | 0.79 | 47.23 | 20.9 | |||
2022.01 (1month after MWA) | NA | 2.24 | 0.97 | 48.2 | 15.2 | |||
2022.03 (3 month after MWA) | 5.13 | 22.8 | 1.03 | 2.19 | 1.08 | 42.7 | 17.9 | |